Novartis

New Novartis data presented at AAD reveals Cosentyx® is superior to Stelara …
Undertreatment, treatment trends, and treatment dissatisfaction among patients with psoriasis and psoriatic arthritis in the United States: findings from the National Psoriasis Foundation surveys, 2003-2011. JAMA Dermatol. 2013; 149(10):1180-1185 ... [...]
1
Like
Save
New Novartis Data Reveals Cosentyx® is Superior to Stelara® in Psoriasis Patients
This is an important milestone in the treatment of psoriasis, a skin disease with significant physical and emotional impact on a patient's life. I am encouraged by the data from the CLEAR study as it validates Cosentyx® as an effective treatment option ... [...]
5
Like
Save
Novartis (NVS) Issues Positive Update from Cosentyx CLEAR Study in Psoriasis
Cosentyx is the first fully human interleukin-17A inhibitor approved for adults to treat moderate-to-severe plaque psoriasis, and was recently approved for the treatment of psoriatic arthritis and ankylosing spondylitis in the EU and US. "Cosentyx ... [...]
1
Like
Save
New Novartis data show Cosentyx demonstrated sustained superiority in skin …
... antagonist approved to treat adult patients with moderate to severe plaque psoriasis, with almost 15,000 U.S. patients prescribed to date.2 Cosentyx also was recently approved for the treatment of psoriatic arthritis and ankylosing spondylitis in ... [...]
3
Like
Save
Radius Health Firm, Enters Clinical Collaboration With Novartis to Evaluate …
It is also developing RAD1901, a selective estrogen receptor down-regulator/degrader, which is in Phase I clinical trial for the treatment of metastatic breast cancer and other estrogen receptor mediated oncology applications, as well as in Phase II ... [...]
1
Like
Save
Novartis extends lead on psoriasis rivals with a pair of new Cosentyx approvals
The FDA has approved the therapy as a treatment for psoriatic arthritis and ankylosing spondylitis, the Swiss drugmaker said Friday, noting that in the U.S., up to 1% of the general population may be affected by psoriatic arthritis. Half a million are ... [...]
6
Like
Save
Novartis receives FDA nod for ankylosing spondylitis and psoriatic arthritis drug
Novartis announced that the US Food and Drug Administration (FDA) has approved Cosentyx (secukinumab) for the treatment of two new indications - adults with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both ... [...]
3
Like
Save